Discover 709 paid clinical trials in Oklahoma. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Oklahoma offers many options for individuals interested in paid research studies as both healthy participants and those with specific health conditions. Leading research centers in Oklahoma City, Tulsa, and Norman are recruiting volunteers, giving access to the latest treatments and specialized care.
Filter
1
Filter results
Results: 709
FeaturedActive & Responsive
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
for
Overweight, Prediabetic State, Prehypertension,
Location: Boston MA, New Haven CT, Waterbury CT, Hartsdale NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07794579
Phase 3, Recruiting
Active & Responsive
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
for
Preventive Treatment of Migraine
Location: Boca Raton FL, Winter Park FL, Ann Arbor MI,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07729462
Phase 3, Recruiting
Active & Responsive
Postnatal Exercise to Activate Baby's Brown Fat
for
Childhood Obesity Prevention, Childhood Obesity,
Location: Boston MA, Oklahoma City OK
Sponsor: Joslin Diabetes Center
Sex: Female
Age: 18 - 45
Code: NCT07467694
Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Springfield MA, Saint Johnsbury VT, Lebanon NH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase 2, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Waterford CT, New Haven CT, Stony Brook NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase 2, Recruiting
Active & Responsive
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
for
Crohn's Disease
Location: Kentville, Boston MA, Providence RI, Levis,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 16 - 70+
Code: NCT06430801
Phase 3, Recruiting
Active & Responsive
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Saint Johnsbury VT, Lebanon NH, Commack NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase 3, Recruiting
Active & Responsive
Reset Challenge: Reducing High-risk Drinking for Cancer Prevention
for
Alcohol Drinking, Heavy Drinking, Binge Drinking
Location: Tulsa OK
Sponsor: University of Oklahoma
Sex: All
Age: 18 - 70+
Code: NCT07591428
Recruiting
Active & Responsive
The Artisse⢠Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
for
Intracranial Aneurysm
Location: Boston MA, New Haven CT, Stony Brook NY, New York NY,
Sponsor: Medtronic Neurovascular Clinical Affairs
Sex: All
Age: 18 - 70+
Code: NCT02998229
Recruiting
Active & Responsive
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
for
Smoking Cessation Intervention, Pain,
Location: Tulsa OK
Sponsor: University of Oklahoma
Sex: All
Age: 18+
Code: NCT07080788
Recruiting
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer